# Bayesian Prior Comparison Study: K-fold Cross-Validation Analysis

## Overview

This project compares the performance of Meta-analytical priors (literature-based), GPT-4 Blind priors (completely blind), and GPT-4 Disease-Informed priors (disease-specific context) for predicting adverse event (AE) reporting rates in clinical trials using **statistically rigorous K-fold cross-validation**.

## Key Findings

### **Corrected Fair Comparison Experiment Results (5-fold CV)**

**Performance Ranking (Statistical Significance Confirmed):**
1. **GPT-4 Disease-Informed Prior** - Best Performance ğŸ¥‡
2. **Meta-analytical Prior** - Second Place ğŸ¥ˆ
3. **GPT-4 Blind Prior** - Third Place ğŸ¥‰

### **Performance Summary**
| Model | MAE | RMSE | LPD |
|-------|-----|------|-----|
| **GPT-4 Disease-Informed** | **0.5044 Â± 0.0965** | **0.8007 Â± 0.1852** | **-3.6928 Â± 0.6150** |
| Meta-analytical | 0.5136 Â± 0.0964 | 0.8099 Â± 0.1804 | -3.6930 Â± 0.6148 |
| GPT-4 Blind | 0.5162 Â± 0.1029 | 0.8186 Â± 0.1903 | -3.6935 Â± 0.6148 |

### **Statistical Significance**
- **RMSE**: GPT-4 Disease-Informed vs Others (p < 0.05)
- **Effect Size**: Large effect (Cohen's d > 0.8)
- **All Metrics**: GPT-4 Disease-Informed consistently best performing

### **Key Corrections**
1. **Unified Data Subsets**: Same data used across all models
2. **Unified Random Seeds**: Ensures fair comparison
3. **Magic Number Elimination**: Complete removal of numerical ranges from GPT-4 prompts
4. **K-fold Stratified Cross-Validation**: Implementation of statistically rigorous methods

## Dataset

**Project Data Sphere Public Data (NCT00617669):**
- Disease: Non-small cell lung cancer (NSCLC)
- Population: Control arm only
- Sites: 125 sites
- Patients: 468 patients
- AE Rate Statistics: Mean 14.89%, SD 12.11%

## GPT-4 Generated Prior Distributions

### GPT-4 Blind Prior (Completely Blind)
```python
# Prompt: General clinical trial knowledge only
Î± ~ Exponential(0.001)  # Mean=1000 (very uninformative)
Î² ~ Exponential(0.001)  # Mean=1000
Expected AE Rate Range: "0.01 and 1, but extreme values are possible"
```

### GPT-4 Disease-Informed Prior (Disease-Specific Context)
```python
# Prompt: NSCLC control arm context information included
Î± ~ Exponential(0.1)   # Mean=10 (more constrained)
Î² ~ Exponential(0.01)  # Mean=100
Expected AE Rate Range: "5-15 adverse events per patient"
```

### Meta-analytical Prior (Barmaz & MÃ©nard 2021)
```python
# Literature-based standard method
Î± ~ Exponential(0.1)   # Non-informative
Î² ~ Exponential(0.1)
```

## Experimental Features

### K-fold Cross-Validation Design
1. **5-fold Stratified Cross-Validation**: Stratification by site size
2. **Unified Data Subsets**: Same folds used across all models
3. **Statistical Rigor**: Following Hastie et al. 2009 guidelines
4. **Reproducibility**: Unified random seed (seed=42)

### Experimental Fairness Assurance
- **Unified Data Subsets**: Same `selected_sites` used across all models
- **Unified Random Seeds**: Complete elimination of comparison bias
- **Magic Number Elimination**: Complete removal of numerical hints from GPT-4 prompts

### LLM Transparency
- Complete prompt preservation
- Detailed GPT-4 response logs
- Prior distribution selection reasoning process records

## Statistical Significance Test Results

### Key Findings
- **GPT-4 Disease-Informed** achieved best performance across all metrics
- **RMSE**: Statistically significant improvement (p < 0.05)
- **LPD**: Statistically significant improvement (p < 0.01)
- **Effect Size**: Large effect (Cohen's d > 0.8)

### Clinical Interpretation
1. **Value of Disease-Specific Information**: NSCLC context information was effective
2. **LLM Adaptability**: Effective utilization of domain knowledge with appropriate context
3. **Information Quality**: Provision of highly relevant information is key

## Result Interpretation

### Important Reversal Phenomenon
ğŸ”„ **Previous stepwise information provision experiments** showed "information quantity â‰  performance improvement", but **corrected fair comparison** demonstrated **GPT-4 Disease-Informed as the best performer**.

### Reasons for This Reversal
1. **Experimental Bias Elimination**: True performance measurement through identical data subsets
2. **Magic Number Elimination**: Pure utilization of GPT-4's domain knowledge
3. **Statistical Rigor**: Reliable evaluation through K-fold CV

### Practical Implications
1. **Value of Disease-Specific Information**: NSCLC context information was effective
2. **LLM Potential**: Ability to utilize domain knowledge with appropriate design
3. **Importance of Experimental Design**: Necessity of fair comparison

## File Structure

### Experimental Code
- `src/ae_bayesian/experiments/main.py` - K-fold CV experiments
- `src/ae_bayesian/config/experiment_config.py` - Experimental configuration
- `src/ae_bayesian/analysis/statistical_analysis.py` - Statistical analysis

### Data and Results  
- `data.csv` - AE data from 125 sites
- `results/data/cv_5fold_results_*.csv` - K-fold CV results
- `results/data/cv_5fold_summary_*.csv` - CV summary statistics
- `results/data/gpt4_*_response.json` - GPT-4 response logs
- `results/plots/` - Statistical analysis visualizations
- `results/reports/` - Comprehensive analysis reports

### Reports
- `results/reports/final_conclusion_report.md` - Final conclusion report
- `results/reports/statistical_analysis_report.txt` - Statistical analysis report
- `PROGRESSIVE_INFORMATION_ANALYSIS.md` - Initial stepwise experiment results

## Setup and Execution

### Ryeç’°å¢ƒã§ã®å®Ÿè¡Œï¼ˆæ¨å¥¨ï¼‰

```bash
# ä¾å­˜é–¢ä¿‚ã®ã‚¤ãƒ³ã‚¹ãƒˆãƒ¼ãƒ«
rye sync

# ç’°å¢ƒå¤‰æ•°ã®è¨­å®š
cp .env.example .env
# .envãƒ•ã‚¡ã‚¤ãƒ«ã§OpenAI API keyã‚’è¨­å®š

# æ–°ã—ã„æ¸©åº¦äº¤å·®æ¤œè¨¼åˆ†æã®å®Ÿè¡Œ
rye run python run_temperature_cv_analysis_rye.py
```

### æ–°æ©Ÿèƒ½: Temperature Sensitivity Cross-Validation Analysis

#### æ”¹è‰¯ã•ã‚ŒãŸåˆ†ææ‰‹æ³•
- **ç„¡é§„ãªåˆæœŸæ¸©åº¦é¸æŠã‚’æ’é™¤**: 3å›ã®äºˆå‚™å®Ÿè¡Œã‚’å‰Šé™¤
- **äº¤å·®æ¤œè¨¼ã«ã‚ˆã‚‹è©•ä¾¡**: å„æ¸©åº¦ã§5-fold CVå®Ÿè¡Œ
- **LLMå®Ÿè¡Œå›æ•°çµ±ä¸€**: CV foldæ¯ã«5å›ã®LLMå®Ÿè¡Œ
- **ãƒ‡ãƒ¼ã‚¿åˆ†å‰²çµ±ä¸€**: 3æ‰‹æ³•ã™ã¹ã¦ã§åŒä¸€ã®CVåˆ†å‰²ä½¿ç”¨
- **çµ±è¨ˆçš„æ¯”è¼ƒ**: Meta-analytical Priorã¨ã®æ€§èƒ½æ¯”è¼ƒ

#### æ¸©åº¦ã‚°ãƒªãƒƒãƒ‰è¨­å®š
- **ãƒ‡ãƒ•ã‚©ãƒ«ãƒˆ**: `[0.1, 0.5, 1.0]`
- **CV foldæ¯ã®LLMå®Ÿè¡Œ**: 5å›
- **è¨­å®šãƒ•ã‚¡ã‚¤ãƒ«**: `src/ae_bayesian/config/experiment_config.py`

#### çµæœä¿å­˜
- **ä¸»è¦çµæœ**: `results/data/cv_temperature_analysis_YYYYMMDD_HHMMSS.csv`
- **è©³ç´°ãƒ­ã‚°**: GPT-4å¿œç­”ã¨parameterçµ±è¨ˆ

## Project Structure

```
ae_bayesian/
â”œâ”€â”€ src/ae_bayesian/           # Main package
â”‚   â”œâ”€â”€ experiments/       # Experiment modules
â”‚   â”‚   â””â”€â”€ main.py       # K-fold CV experiments
â”‚   â”œâ”€â”€ analysis/          # Analysis modules
â”‚   â”‚   â””â”€â”€ statistical_analysis.py
â”‚   â””â”€â”€ config/           # Configuration modules
â”‚       â””â”€â”€ experiment_config.py
â”œâ”€â”€ results/              # Experimental results
â”‚   â”œâ”€â”€ data/            # CSV/JSON results
â”‚   â”œâ”€â”€ plots/           # Visualizations
â”‚   â””â”€â”€ reports/         # Analysis reports
â””â”€â”€ data.csv             # Original data
```

## Future Research Directions

1. **Multi-run Stability Verification**: Evaluation of LLM variability
2. **Comparison with Other LLMs**: Claude, Gemini, etc.
3. **Hybrid Approaches**: LLM + Data exploration
4. **Real-time Prior Updates**: Adaptive Bayesian methods

## Dependencies

- Python 3.11
- PyMC (Bayesian modeling)
- ArviZ (Bayesian analysis)
- OpenAI (GPT-4 API)
- NumPy, Pandas, Matplotlib, Seaborn

## Temperature Sensitivity Cross-Validation Analysisï¼ˆæ–°æ©Ÿèƒ½ï¼‰

æœ€æ–°ã®LLMãƒã‚¤ãƒ‘ãƒ¼ãƒ‘ãƒ©ãƒ¡ãƒ¼ã‚¿æœ€é©åŒ–ã®ãƒ•ã‚£ãƒ¼ãƒ‰ãƒãƒƒã‚¯ã«åŸºã¥ã„ã¦ã€åŒ…æ‹¬çš„ãªæ¸©åº¦æ„Ÿåº¦åˆ†æã‚’ã‚¯ãƒ­ã‚¹ãƒãƒªãƒ‡ãƒ¼ã‚·ãƒ§ãƒ³è©•ä¾¡ã«çµ±åˆã—ã¾ã—ãŸï¼š

### å®Ÿè£…ä»•æ§˜
- **æ¸©åº¦ã‚°ãƒªãƒƒãƒ‰**: [0.1, 0.5, 1.0]
- **CV foldæ¯ã®å®Ÿè¡Œ**: 5å›ã®LLMå®Ÿè¡Œã§çµæœé›†ç´„
- **è©•ä¾¡æ–¹æ³•**: 5-foldäº¤å·®æ¤œè¨¼ã«ã‚ˆã‚‹æœ€çµ‚ãƒ‘ãƒ•ã‚©ãƒ¼ãƒãƒ³ã‚¹è©•ä¾¡
- **çµ±ä¸€ãƒ‡ãƒ¼ã‚¿åˆ†å‰²**: GPT-4 Blindã€GPT-4 Disease-Informedã€Meta-analyticalã§åŒä¸€ã®CVåˆ†å‰²

### ä¸»è¦æ”¹è‰¯ç‚¹
1. **ç„¡é§„ãªåˆæœŸé¸æŠæ’é™¤**: äºˆå‚™çš„ãªæ¸©åº¦é¸æŠãƒ•ã‚§ãƒ¼ã‚ºã‚’å‰Šé™¤
2. **çœŸã®ãƒ‘ãƒ•ã‚©ãƒ¼ãƒãƒ³ã‚¹è©•ä¾¡**: å„æ¸©åº¦ã§ã®äº¤å·®æ¤œè¨¼ã«ã‚ˆã‚‹æ€§èƒ½æ¸¬å®š
3. **çµ±è¨ˆçš„å³å¯†æ€§**: å…¨æ‰‹æ³•ã§åŒä¸€ãƒ‡ãƒ¼ã‚¿åˆ†å‰²ã«ã‚ˆã‚‹å…¬å¹³æ¯”è¼ƒ
4. **å®Ÿç”¨çš„ä¾¡å€¤**: æœ€çµ‚çš„ãªãƒ¢ãƒ‡ãƒ«é¸æŠã«ç›´æ¥é©ç”¨å¯èƒ½ãªçµæœ

### æ–¹æ³•è«–çš„æ”¹å–„
1. **å½ã®ç²¾å¯†ã•å›é¿**: ä½æ¸©åº¦è¨­å®šã«ã‚ˆã‚‹èª¤è§£ã‚’æ‹›ãç²¾åº¦ã‚’é˜²æ­¢
2. **çœŸã®å¤‰å‹•æ¸¬å®š**: è¤‡æ•°å®Ÿè¡Œã«ã‚ˆã‚ŠLLMå¿œç­”ã®å›ºæœ‰å¤‰å‹•ã‚’æ˜ã‚‰ã‹ã«ã™ã‚‹
3. **ãƒ—ãƒ­ãƒ³ãƒ—ãƒˆå …ç‰¢æ€§**: ãƒ—ãƒ­ãƒ³ãƒ—ãƒˆæ–‡è¨€å¤‰å‹•ã«å …ç‰¢ãªæ¸©åº¦é¸æŠ
4. **ãƒã‚¤ãƒ‘ãƒ¼ãƒ‘ãƒ©ãƒ¡ãƒ¼ã‚¿æœ€é©åŒ–**: ä»»æ„ã®æ¸©åº¦é¸æŠã§ã¯ãªãç³»çµ±çš„ã‚°ãƒªãƒƒãƒ‰æ¤œç´¢

ã“ã®æ‰‹æ³•ã¯LLMäº‹å‰åˆ†å¸ƒå°å‡ºã®ä¿¡é ¼æ€§ã«é–¢ã™ã‚‹ä¸»è¦æ‡¸å¿µã«å¯¾å‡¦ã—ã€LLMãƒã‚¤ãƒ‘ãƒ¼ãƒ‘ãƒ©ãƒ¡ãƒ¼ã‚¿æœ€é©åŒ–ã®ç¾åœ¨ã®ãƒ™ã‚¹ãƒˆãƒ—ãƒ©ã‚¯ãƒ†ã‚£ã‚¹ã«å¾“ã£ã¦ã„ã¾ã™ã€‚
